Chronic News and Research

RSS

Responsible Opioid Prescribing eBook from FSMB Foundation

The Federation of State Medical Boards (FSMB) Foundation announced today its publication of an eBook edition of "Responsible Opioid Prescribing: A Clinician's Guide" for Kindles, Nooks, iPads and other popular platforms.

13 Dec 2012

Mathematical models can improve efficiency and quality of healthcare

Healthcare organizations face huge challenges during the upcoming years: the constant cost increases must be halted, while at the same time patients are becoming more and more demanding, and hospitals nationwide still cope with some 2000 avoidable deaths each year. Simultaneously improving efficiency and quality of care would seem to be a contradiction in terms. Yet Kortbeek shows in his thesis, along a number of case studies, that this is absolutely doable. The key is developing and applying mathematical models.

13 Dec 2012

Patients with multiple sclerosis have low levels of Egr2/3 protein in T lymphocytes

Researchers from Queen Mary, University of London have discovered that two proteins which are believed to play a key role in controlling the body's immune response are found in lower levels in T lymphocytes from patients with multiple sclerosis (MS).

13 Dec 2012

ACOEM initiative provides tools and resources to help employers address obesity

As part of its year-long campaign addressing chronic disease in the workplace, the American College of Occupational and Environmental Medicine (ACOEM) is providing tools and resources to help employers identify and respond to the impact of obesity on worker health and productivity. Such resources and tools are of special relevance at this time of the year.

13 Dec 2012

Researchers discover a trigger by which the HCV enters liver cells

Researchers at the University of Southern California (USC) have discovered a trigger by which the Hepatitis C virus enters liver cells ─ shedding light on how this serious and potentially deadly virus can begin to damage the liver.

13 Dec 2012

TKI-resistant human leukemia stem cells are the source of genomic instability

An international team of scientists, led by researchers from Temple University School of Medicine, has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs.

12 Dec 2012

Spotlight on acute respiratory distress syndrome in low-risk surgery

Postoperative acute respiratory distress syndrome is rare in patients undergoing low-risk surgery, but still carries a very high mortality rate, a large study shows.

12 Dec 2012

Bipolar and borderline personality disorder associated with unemployment

Unemployment poses a significant burden on the public no matter what the cause. But for those who have been diagnosed with a psychiatric illness, chronic unemployment is often coupled with significant health care costs. A Rhode Island Hospital study compared unemployment rates among those with various psychiatric disorders, and found that borderline personality disorder is associated with as much unemployment as bipolar disorder.

12 Dec 2012

Examining Americans' health: Longer, but sicker, lives; Childhood obesity drops

A new report finds Americans may be living longer thanks to medical advances, but they may also be sicker. Meanwhile, childhood obesity may be dropping in several cities around the nation.

12 Dec 2012

Tiotropium benefits patients with chronic obstructive pulmonary disease

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for inhalation. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether tiotropium offers a perceptible advantage to patients compared to a dummy medication (placebo) and to other COPD drugs.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Pay attention to pregnant workers with pelvic girdle pain

Researchers say that clinicians must give more attention to working women who experience pelvic girdle pain during pregnancy to prevent recurrence during the postpartum period.

11 Dec 2012

New approach can reduce occupational health hazard risks in construction workers

"Some of the most pressing occupational health hazard risks in construction" are associated with masonry operations, asphalt roofing, and welding, wrote Deborah Young-Corbett in an article recently accepted by the Journal of Civil Engineering and Management.

11 Dec 2012

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

A nanomaterial engineered by researchers at Duke can help regulate chloride levels in nerve cells that contribute to chronic pain, epilepsy, and traumatic brain injury.

11 Dec 2012

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Chronic News and Research

Responsible Opioid Prescribing eBook from FSMB Foundation

Mathematical models can improve efficiency and quality of healthcare

Patients with multiple sclerosis have low levels of Egr2/3 protein in T lymphocytes

ACOEM initiative provides tools and resources to help employers address obesity

Researchers discover a trigger by which the HCV enters liver cells

TKI-resistant human leukemia stem cells are the source of genomic instability

Spotlight on acute respiratory distress syndrome in low-risk surgery

Bipolar and borderline personality disorder associated with unemployment

Examining Americans' health: Longer, but sicker, lives; Childhood obesity drops

Tiotropium benefits patients with chronic obstructive pulmonary disease

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Pay attention to pregnant workers with pelvic girdle pain

New approach can reduce occupational health hazard risks in construction workers

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Research unveils key gaps in continuity of care for sickle cell patients

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News